Serum Institute cuts Ravinder Heights stake by 2% in open market
The vaccine maker sold 1.27 million shares on June 16, lowering its holding from 9.39% to 7.32%. For a nano-cap real estate firm with collapsing revenue, a notable investor exit is a red flag.
— 1 earlier story on Ravinder Heights Ltd. →What's new
- Serum Institute sold 1.27 million shares (2.07%) of Ravinder Heights on June 16 via open market.
- The sale reduces Serum's stake from 9.39% to 7.32% in the real estate company.
- Disclosure under SEBI substantial acquisition norms; the exit exceeds 1% materiality threshold for nano-caps.
Why this matters
Serum Institute is not a passive financial investor; its stake reduction signals a deliberate portfolio shift. For Ravinder Heights, a ₹278 cr market-cap company with trailing revenue down 90.5%, losing a marquee stakeholder compounds the fundamental weakness. The stock will now carry a stigma that a long-term backer chose to leave.
What we're watching
- Whether Serum continues to sell further tranches in the coming weeks.
- Any response from Ravinder Heights management; a buyback or promoter pledge could counter the signal.
- Impact on stock liquidity and valuation multiples given the thin float.
The full read
Serum Institute of India sold 1.27 million shares ( 2.07% ) of Ravinder Heights on June 16. The open-market sale brings Serum's holding down to 7.32% from 9.39%, a notable reduction for a company with ₹278 cr market cap and trailing revenue that fell 90.5%. The stake, worth roughly ₹5.7 crore, exceeds the 1% materiality threshold for nano-caps, making the disclosure necessary. Ravinder Heights swung to a profit last year on one-time subsidiary revenue, but the core real estate business remains under pressure. When a shareholder of Serum's pedigree trims, the signal is hard to ignore.
Questions answered
- How much did Serum Institute sell and for how much?
- Serum sold 1.27 million shares (2.07% of equity) on June 16. Based on market cap of ₹278 cr, the stake is worth roughly ₹5.7 crore.
- Why is Serum's stake sale significant for a small real estate company?
- Serum Institute is a prominent private entity. For a nano-cap with falling revenue (trailing revenue down 90.5%), a well-known investor reducing stake can spook other shareholders and signal waning confidence in the business.
- What is Ravinder Heights' financial condition?
- The company has a market cap of ₹278 cr, zero debt, but trailing revenue down 90.5% and PAT down 223.8%. In FY26, it posted a one-time profit of ₹48.89 cr from subsidiary revenue, masking underlying weakness.
- Does this sale require regulatory disclosure?
- Yes, the transaction was disclosed under SEBI's substantial acquisition of shares and takeovers regulations. Serum's holding fell from 9.39% to 7.32%, crossing the 5% threshold band.
Ravinder Heights Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on RVHL →- 19 Jun 2026 · 10:50 AM IST Serum Institute cuts Ravinder Heights stake by 2% in open market
- 20d ago Ravinder Heights swings to ₹49 cr profit on one-time subsidiary revenue